Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2016Science China Life SciencesOpen Access

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKaichao FengChinese PLA General HospitalYGYelei GuoChinese PLA General HospitalHDHanren DaiMinistry of Education of the People's Republic of China

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Feng et al. (2016) studied this question.

synapsesocial.com/papers/6a0ea65faa1655e5fb229b97https://doi.org/10.1007/s11427-016-5023-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry2012 · 146 citations
  2. 2Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes2002 · 2,851 citations
  3. 3New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer2011 · 351 citations
  4. 4Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia2011 · 104 citations
  5. 5Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma2015 · 1,003 citations